Last updated: June 18, 2026
Executive summary: Case 1:25-cv-00387 is a 2025 patent-litigation filing by InfoRLife SA against Sagent Pharmaceuticals in the context of an FDA-oriented Hatch-Waxman dispute. The docket is currently too sparse to support a complete, litigation-grade analysis tied to specific asserted patents, claims, and scheduled events.
What is InfoRLife SA v. Sagent Pharmaceuticals 1:25-cv-00387 about?
Answer: The case is docketed as a federal patent infringement action filed in S.D. Florida in 2025, styled InfoRLife SA v. Sagent Pharmaceuticals under case number 1:25-cv-00387.
Where is the case filed and what court governs?
- Court: U.S. District Court for the Southern District of Florida
- Case number: 1:25-cv-00387
- Parties: InfoRLife SA (plaintiff) vs Sagent Pharmaceuticals (defendant)
What litigation posture does the case reflect?
Without the complaint text and the filed patent list, the only defensible characterization is that it is a newly docketed patent action consistent with Hatch-Waxman framework (typical triggers include ANDA/Orange Book-driven disputes).
Which patents are asserted in InfoRLife SA v. Sagent Pharmaceuticals (1:25-cv-00387)?
Answer: Specific asserted patent numbers, expiration dates, and claim categories are not available in the provided record.
How to interpret “asserted patent” gaps in early docketing
For high-stakes analysis, the asserted-patent bundle drives:
- infringement theory (composition vs formulation vs method-of-use),
- standard of claim construction,
- invalidity defenses (anticipation, obviousness, written description, enablement),
- and design-around pathways for the generic.
No such mapping can be produced here without the asserted-patent identifiers.
What is the litigation timeline and procedural schedule for 1:25-cv-00387?
Answer: The provided information does not include docket events (motions, claim construction, scheduling order, preliminary injunction posture, or trial date).
What timeline elements should be checked for Hatch-Waxman cases
A litigation-grade timeline typically includes:
- complaint and initial service dates,
- defendant answer and affirmative defenses,
- Rule 12 motions (if any),
- scheduling order,
- Markman/claim construction date,
- expert report deadlines,
- dispositive motion dates,
- and any preliminary injunction briefing.
Those items are not present in the provided record.
How strong is InfoRLife’s patent estate in this dispute?
Answer: Strength cannot be evaluated because the asserted patents and relevant claim construction history are not specified.
What a strength analysis normally requires
A proper estate assessment usually decomposes:
- number of active patents at filing (and surviving beyond the earliest expiration),
- remaining term and PTA/PTE impact,
- common prior art clusters in the asserted patents,
- prosecution history estoppel and disclaimer risk,
- enforceability issues (inequitable conduct allegations, statutory bars),
- and claim breadth (independent claim scope vs narrow dependent claims).
No asserted-patent identifiers are available in the provided record.
What is the potential generic entry risk for Sagent if InfoRLife’s patents expire soon?
Answer: Expiration timing cannot be tied to risk without the asserted patents.
How generic entry risk is normally calculated
Risk depends on:
- earliest possible “launch safe date” based on patent expiries and exclusivities,
- whether any asserted patents have been found or are likely to be found infringed and not invalid,
- whether there are ongoing claim-construction outcomes,
- and whether any settlement triggers are included in the case docket.
Those elements are not available.
What is the Orange Book and FDA status relevant to this case?
Answer: FDA product identification (reference listed drug, strength, dosage form) is not provided, so Orange Book status cannot be matched to 1:25-cv-00387.
Why Orange Book mapping is central
For Hatch-Waxman suits, investors and litigators need:
- the specific RLD and NDA/BLA,
- listed Orange Book patents (drug substance, drug product, and method-of-use),
- the paragraph certification(s),
- and any FDA approval timelines that intersect with litigation stay frameworks.
No such product mapping is available in the provided record.
What Paragraph IV challenges or settlement terms exist for this dispute?
Answer: No Paragraph IV certification details or settlement information is available in the provided record.
What to extract from Paragraph IV-related dockets
Key items typically include:
- the specific patents subject to Paragraph IV,
- the statutory basis for alleged infringement (e.g., product claims),
- the litigation settlement agreement terms (pay-for-delay, carve-outs),
- and any agreed design-around limitations.
Not provided.
Which other companies are involved or co-litigants in related cases?
Answer: The provided record does not list related defendants, co-pending suits, or transfer/consolidation details.
What co-litigant tracking usually finds
- parallel suits against other ANDA filers,
- related patent infringement actions in other districts,
- shared prior art and overlapping asserted patents across cases.
Not provided.
Case comparison: How does this dispute compare with other InfoRLife SA patent actions against generics?
Answer: Comparative analysis cannot be produced without:
- the asserted drug/product identity tied to this docket,
- the patent numbers,
- and the outcomes or typical positions in InfoRLife’s prior cases.
Not provided.
Key Takeaways
- 1:25-cv-00387 is a 2025 federal patent litigation filed by InfoRLife SA against Sagent Pharmaceuticals in the Southern District of Florida.
- A litigation-grade analysis requires the asserted patent list, product/RLD mapping, and procedural docket events, none of which are included in the provided record.
- No conclusions can be drawn on patent strength, infringement/validity posture, Orange Book status, Paragraph IV certifications, settlement terms, or entry timing.
FAQs
- What court and venue is 1:25-cv-00387 in, and what does that imply for procedural timelines?
- How do investors typically validate whether 1:25-cv-00387 is tied to an ANDA Paragraph IV dispute?
- What docket items signal claim construction and trial readiness in Hatch-Waxman cases?
- How is generic launch risk modeled when asserted patents include method-of-use claims?
- What patent categories (composition, formulation, method-of-use) most often drive settlement leverage in Sagent-related litigations?
References (APA)
- InfoRLife SA v. Sagent Pharmaceuticals, No. 1:25-cv-00387 (S.D. Fla. filed 2025).
